Sun Pharma Q2 Results Preview: revenues to be supported by the healthy US and domestic sales
Q2 Results Preview: Sun Pharma is expected to report sales growth of 10% year-on-year as per PhillipCapital estimates. Margins, however, may correct on account of lower R&D base and remediation charges. The resultant Ebitda falls by 4% and net profit by 3% year-on-year
DNA News Desk
0
10
Q2 Results Preview: Sun Pharma is expected to report sales growth of 10% year-on-year as per PhillipCapital estimates. Margins, however, may correct on account of lower R&D base and remediation charges. The resultant Ebitda falls by 4% and net profit by 3% year-on-year
